Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for epinephrine and will help in efforts to gain regulatory approval for ARS-1 (known as Neffy™ in the U.S.) around the world
PR Newswire
SAN DIEGO, Sept. 22, 2020
